Excel Industries (EXCELINDUS)

FairStock Score: 22/100 — RISKY

Score breakdown: P/E: 2/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Trades below book value: P/B 0.96 vs. book value ₹990.22, offering a margin of safety.
• Near-zero leverage with Debt/Equity of 0.01, keeping the balance sheet conservative.
• Strong reported growth: sales up 18.9% and profit up 36.13%, with PEG of 0.57.
• Piotroski F-Score of 7/9 suggests solid financial health and improving fundamentals.
• Promoter holding of 52.69% aligns management with minority shareholders.

Concerns

• Low ROE of 8.48% and ROCE of 7.11% indicate weak competitive advantage and pricing power.
• Latest quarter net profit of ₹8 Cr on sales of ₹234 Cr implies thin and possibly volatile margins.
• P/E of 15.80 is not deeply cheap; valuation depends on continued growth.
• FairStock Score of 45/100 is mixed, and the 52-week range shows significant price volatility.

AI Analysis

At first glance, this is exactly the kind of stock Graham would ask me to examine: it trades at ₹955.30, just below book value of ₹990.22, with debt/equity of 0.01. The P/B of 0.96 means I am getting a rupee of assets for 96 paise. The P/E of 15.80, with a PEG of 0.57, suggests the market is not paying full freight for the 36% profit growth and 18.9% sales growth. Promoters own 52.69%, so interests are aligned. But let me slow down. ROE of 8.48% and ROCE of 7.11% are not the kind of returns that signal a durable moat. A wonderful business should be able to earn well above its cost of capital. The latest quarter shows net profit of ₹8 Cr on sales of ₹234 Cr — less than 3.5% net margin — so the recent profit growth may be lumpy. The Piotroski F-score of 7/9 is healthy and points to improving fundamentals, but I must not confuse a strong year with a strong business. I would call this a cyclical specialty-chemical business, not a compounding machine. The low leverage is a source of comfort; if the industry turns down, this company can survive. The other side is that with low returns on capital, there is little cushion for value surprises. I need to see margins expand, ROCE move consistently higher, and quarterly profit accelerate before I commit serious capital. If the company can continue to grow sales and convert that to profit, the current price may prove cheap; if not, book value support is my only net. I will keep it on the watchlist.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer